Thursday, April 21, 2016

CCO - Our Expert Picks in HCV Now Available From Barcelona‏ EASL 2016*

CCO Independent Conference Coverage: Clinical Impact of New Data From EASL 2016*

Capsule Summaries

David R. Nelson, MD
Nancy Reau, MD, FAASLD, AGAF

Examine key data emerging from the most important HCV studies presented in Barcelona, as selected by the experts. Capsule Summaries available to date include:

C-EDGE Head to Head: Grazoprevir/Elbasvir Superior to Sofosbuvir + PegIFN/RBV in the Treatment of HCV Genotype 1 and 4 Infection
Interferon-free therapy demonstrates superior efficacy and safety to interferon-containing regimen in comparative study.
Read More

GS-1168/1169: 12 Weeks of Sofosbuvir/Velpatasvir + GS-9857 Highly Effective Across Genotypes in Treatment-Experienced HCV-Infected Patients
Novel all-oral, multiclass regimen effective regardless of HCV genotype, cirrhosis status, and extent of treatment experience.
Read More

ASTRAL-5: 12 Weeks of Sofosbuvir/Velpatasvir Safe, Highly Effective in Patients With HCV/HIV Coinfection on Stable ART
Treatment was well tolerated without renal perturbations or HIV virologic rebound.
Read More

HEPA-C: Decompensated Cirrhosis Associated With Decreased Response and Increased Risk of Severe Outcomes After DAA Therapy in Real-World Setting
MELD score of ≥ 18 predicted increased risk of severe adverse events or death.
Read More

Real-World Data Suggest Feasibility of Individualized Retreatment After IFN-Free DAA Combination Failure in Genotypes 1 and 3 HCV
Selecting the retreatment regimen based on resistance analysis revealed DAA combination regimens likely to be effective after failure of an initial interferon-free DAA combination regimen.
Read More

HCV-TARGET: Baseline RAVs Are Frequently Detected in Patients With Genotype 1 HCV But Have Limited Effect on Efficacy of LDV/SOF or SMV + SOF ± RBV
Little evidence that specific variants influence response to sofosbuvir-containing regimens, although Y93C/H/N RAV may reduce effectiveness of ledipasvir/sofosbuvir.
Read More

SURVEYOR-II: 100% SVR12 Rate With Once-Daily ABT-493 + ABT-530 ± Ribavirin in Treatment-Naive Patients With Genotype 3 HCV Infection and Compensated Cirrhosis
Presence of baseline NS3 and/or NS5A variants did not impact efficacy.
Read More

HepNet IV: 6-Week Regimen of Ledipasvir/Sofosbuvir Highly Effective in Acute Genotype 1 HCV Monoinfection
A short course of ledipasvir/sofosbuvir achieved an SVR12 rate of 100% against genotype 1 HCV with rapid normalization of ALT and bilirubin in most patients.
Read More

No comments:

Post a Comment